Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: Release profile and pharmacological modulation

European Journal of Haematology

Volumn 84, Issue 3, 2010, Pages 239-251

  Reikvam, Håkon ^a   Hatfield, Kimberley J ^a,b   Øyan, Anne M ^a,b   Kalland, Karl H ^a,b   Kittang, Astrid O ^a,b   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukemia; Angiogenesis; Angiopoietin; Chemokines; Chemosensitivity; Matrix metalloproteases; NF B; Tissue inhibitors of metalloproteases

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CXCL2 CHEMOKINE; GELATINASE A; IMMUNOGLOBULIN F(AB) FRAGMENT; INGENOL 3 ANGELATE; MATRIX METALLOPROTEINASE; PEP 005; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CELL; CELL CULTURE; CELL DIFFERENTIATION; CHEMOSENSITIVITY; COCULTURE; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CELLS, CULTURED; CHEMOKINES; COCULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; CYTARABINE; DITERPENES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; PROTEASE INHIBITORS; PYRAZINES; QUINOXALINES; RECEPTOR, TIE-2; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED;

EID: 76249107512     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01382.x     Document Type: Article

References (48)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006 368 : 1894 1907.
2. Shih TT, Hou HA, Liu CY, et al. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 2009 113 : 3161 3167.
3. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000 95 : 309 313.
4. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer 2008 113 : 1605 1613.
5. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005 115 : 849 860.
6. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 2004 50 : 87 100.
7. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001 13 : 534 540.
8. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004 4 : 540 550.
9. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007 82 : 1375 1381.
10. Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling UM, Schuch G, Hossfeld DK, Fiedler W. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 2005 23 : 1109 1117.
11. Hatfield KJ, Hovland R, Oyan AM, Kalland KH, Ryningen A, Gjertsen BT, Bruserud O. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008 22 : 287 293.
12. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996 87 : 1161 1169. (Pubitemid 27010100)
13. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997 277 : 55 60.
14. Eklund L, Olsen BR. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006 312 : 630 641.
15. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009 27 : 3557 3565.
16. Krug U, Serve H, Muller-Tidow C, Mesters RM, Steffen B, Buchner T, Berdel WE. New molecular therapy targets in acute myeloid leukemia. Recent Results Cancer Res 2007 176 : 243 262.
17. Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB, Gjertsen BT, Bruserud O. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007 136 : 814 828.
18. Reikvam H, Olsnes AM, Gjertsen BT, Ersvær E, Bruserud Ø. Nuclear Factor-κB signaling - a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. Crit Rev Oncog 2009 15 : In press.
19. Olsnes AM, Ersvaer E, Ryningen A, Paulsen K, Hampson P, Lord JM, Gjertsen BT, Kristoffersen EK, Bruserud O. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009 145 : 761 774.
20. Travaglino E, Benatti C, Malcovati L, Della Porta MG, Galli A, Bonetti E, Rosti V, Cazzola M, Invernizzi R. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol 2008 80 : 216 226.
21. Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, Turner AR, Zhang MC, Edwards DR, Kossakowska AE. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 1999 105 : 402 411.
22. Ries C, Loher F, Zang C, Ismair MG, Petrides PE. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999 5 : 1115 1124.
23. Marquez-Curtis LA, Dobrowsky A, Montano J, Turner AR, Ratajczak J, Ratajczak MZ, Janowska-Wieczorek A. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol 2001 115 : 595 604.
24. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003 88 : 416 428.
25. Bruserud O, Gjertsen BT. New strategies for the treatment of acute myelogenous leukemia: differentiation induction - present use and future possibilities. Stem Cells 2000 18 : 157 165.
26. Bruserud O, Ryningen A, Wergeland L, Glenjen NI, Gjertsen BT. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004 89 : 391 402. (Pubitemid 38798543)
27. Bruserud O, Ryningen A, Olsnes AM, Stordrange L, Oyan AM, Kalland KH, Gjertsen BT. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007 92 : 332 341.
28. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001 276 : 37258 37265.
29. Oyan AM, Anensen N, Hellem Bo T, Stordrange L, Jonassen I, Bruserud O, Kalland KH, Gjertsen BT. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 2009 9 : 77.
30. Oyan AM, Bo TH, Jonassen I, Ulvestad E, Gjertsen BT, Kalland KH, Bruserud O. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry B Clin Cytom 2005 64 : 18 27.
31. Gjertsen BT, Oyan AM, Marzolf B, et al. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. J Hematother Stem Cell Res 2002 11 : 469 481.
32. Olsnes A, Hatfield K, Bruserud O The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J BUON 2009 14 (Suppl. 1 131 140.
33. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008 1 : re6.
34. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003 22 : 153 166. (Pubitemid 36561055)
35. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003 45 : 227 244.
36. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005 97 : 1093 1107.
37. Aref S, El-Sherbiny M, Mabed M, Menessy A, El-Refaei M. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion. Hematology 2003 8 : 385 391.
38. Paupert J, Mansat-De Mas V, Demur C, Salles B, Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008 7 : 1047 1053.
39. Stefanidakis M, Karjalainen K, Jaalouk DE, Gahmberg CG, O'Brien S, Pasqualini R, Arap W, Koivunen E. Role of leukemia cell invadosome in extramedullary infiltration. Blood 2009 114 : 3008 3017.
40. Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T. Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999 19 : 4395 4400.
41. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, Walker H. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999 107 : 69 79.
42. Song JH, Kim SH, Cho D, Lee IK, Kim HJ, Kim TS. Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2. Int J Cancer 2009 125 : 1074 1081.
43. Aref S, Osman E, Mansy S, Omer N, Azmy E, Goda T, El-Sherbiny M. Prognostic relevance of circulating matrix metalloproteinase-2 in acute myeloid leukaemia patients. Hematol Oncol 2007 25 : 121 126.
44. Lin LI, Lin DT, Chang CJ, Lee CY, Tang JL, Tien HF. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002 117 : 835 841.
45. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005 5 : 229 248.
46. Olsnes AM, Ryningen A, Ersvaer E, Bruserud O. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22. J Interferon Cytokine Res 2008 28 : 297 310.
47. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000 96 : 2673 2681.
48. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007 13 : 333 346.